Cargando…

Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors

Diabetic kidney disease remains the leading cause of end‐stage kidney disease and a major risk factor for cardiovascular disease. Large cardiovascular outcome trials and dedicated kidney trials have shown that sodium‐glucose cotransporter (SGLT)2 inhibitors reduce cardiovascular morbidity and mortal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scholtes, Rosalie A., van Baar, Michaël J. B., Kok, Megan D., Bjornstad, Petter, Cherney, David Z. I., Joles, Jaap A., van Raalte, Daniël H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026736/ https://www.ncbi.nlm.nih.gov/pubmed/33283420 http://dx.doi.org/10.1111/nep.13839

Ejemplares similares

Glucosuria Interferes With Measurement of Effective Renal Plasma Flow Using para-Aminohippuric Acid, With a Focus on SGLT2 Inhibitors
por: Scholtes, Rosalie A., et al.
Publicado: (2020)

Plasma uric acid and renal haemodynamics in type 2 diabetes patients
por: Suijk, Danii LS, et al.
Publicado: (2019)

Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND
por: Sen, Taha, et al.
Publicado: (2022)

Postprandial renal haemodynamic effects of the dipeptidyl peptidase‐4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double‐blind trial
por: Muskiet, Marcel H. A., et al.
Publicado: (2021)

Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes
por: van Raalte, Daniël H, et al.
Publicado: (2020)

The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet
por: Scholtes, Rosalie A., et al.
Publicado: (2022)

Erratum. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care 2018;41:1543–1556
por: van Baar, Michaël J.B., et al.
Publicado: (2019)

Renal haemodynamic response to sodium‐glucose cotransporter‐2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials
por: van der Aart‐van der Beek, Annemarie B., et al.
Publicado: (2021)

Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists
por: van Baar, Michaël J. B., et al.
Publicado: (2019)

Skin microvascular function and renal hemodynamics in overweight patients with type 2 diabetes: A cross‐sectional study
por: Bouman, Emma J., et al.
Publicado: (2021)

Tubuloglomerular Feedback in Renal Glucosuria: Mimicking Long-term SGLT-2 Inhibitor Therapy
por: Neuwirt, Hannes, et al.
Publicado: (2019)

The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes
por: van Raalte, Daniël H., et al.
Publicado: (2019)

Renal sinus fat and renal hemodynamics: a cross-sectional analysis
por: Spit, Karlinde A., et al.
Publicado: (2019)

Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial
por: Scholtes, Rosalie A., et al.
Publicado: (2021)

Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
por: Mosterd, Charlotte M., et al.
Publicado: (2020)

Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection
por: Sridhar, Vikas S., et al.
Publicado: (2020)

Endogenous Fructose Metabolism Could Explain the Warburg Effect and the Protection of SGLT2 Inhibitors in Chronic Kidney Disease
por: Nakagawa, Takahiko, et al.
Publicado: (2021)

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
por: Yau, Kevin, et al.
Publicado: (2022)

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
por: Yau, Kevin, et al.
Publicado: (2022)

The effects of dapagliflozin on cardio‐renal risk factors in patients with type 2 diabetes with or without renin‐angiotensin system inhibitor treatment: a post hoc analysis
por: Scholtes, Rosalie A., et al.
Publicado: (2019)

Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
por: Ghezzi, Chiara, et al.
Publicado: (2018)

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
por: Tonneijck, Lennart, et al.
Publicado: (2016)

Mechanisms underlying the blood pressure‐lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial
por: Scholtes, Rosalie A., et al.
Publicado: (2022)

Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
por: Cherney, David, et al.
Publicado: (2017)

SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence
por: Kalay, Zeynepgul, et al.
Publicado: (2022)

SGLT2 Inhibition in Patients With Type 2 Diabetes Mellitus Post-Nephrectomy: A Single-Center Case Series
por: Škrtić, Marko, et al.
Publicado: (2021)

OR31-06 Gender-Affirming Hormone Therapy Affects Serum Cystatin C-based eGFR In Transgender Individuals
por: van Eeghen, Sarah A, et al.
Publicado: (2023)

Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
por: van der Hoek, Sjoukje, et al.
Publicado: (2023)

Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors
por: Vargas-Delgado, Ariana P., et al.
Publicado: (2023)

Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
por: Bailey, Clifford J., et al.
Publicado: (2022)

Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans
por: Lu, Yasong, et al.
Publicado: (2014)

Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042–2050
por: Tonneijck, Lennart, et al.
Publicado: (2019)

Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
por: Oranje, Paul, et al.
Publicado: (2019)

LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2
por: Powell, David R, et al.
Publicado: (2015)

SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits
por: Leoncini, Giovanna, et al.
Publicado: (2021)

SGLT2 inhibitors and renal complications in type 1 diabetes
por: Petrie, John R
Publicado: (2020)

Hereditary renal glycosuria, diabetes and responses to SGLT2 inhibitor
por: Ren, Qian, et al.
Publicado: (2022)

Protective role of female gender in programmed accelerated renal aging in the rat
por: Pijacka, Wioletta, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mvk6gmck4ejgoaa36a5uthsgh0